These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparative effects of cilostazol and aspirin on the impairment of endothelium-dependent cerebral vasodilation caused by acute cigarette smoking in rats. Iida H, Iida M, Takenaka M, Fukuoka N, Dohi S. J Thromb Thrombolysis; 2010 May; 29(4):483-8. PubMed ID: 19669865 [Abstract] [Full Text] [Related]
3. Angiotensin II type 1 (AT1)-receptor blocker prevents impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking in rats. Iida H, Iida M, Takenaka M, Fujiwara H, Dohi S. Life Sci; 2006 Feb 16; 78(12):1310-6. PubMed ID: 16213531 [Abstract] [Full Text] [Related]
13. [Effectiveness and safety of varenicline for smoking cessation]. Christalla P, Dewenter M, El-Armouche A. Dtsch Med Wochenschr; 2012 May 16; 137(18):940-4. PubMed ID: 22492478 [Abstract] [Full Text] [Related]
14. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Keating GM, Lyseng-Williamson KA. Pharmacoeconomics; 2010 May 16; 28(3):231-54. PubMed ID: 20108995 [Abstract] [Full Text] [Related]
17. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K. Arch Intern Med; 2010 May 16; 166(15):1571-7. PubMed ID: 16908789 [Abstract] [Full Text] [Related]
18. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR. Arch Intern Med; 2010 May 16; 166(15):1561-8. PubMed ID: 16908788 [Abstract] [Full Text] [Related]
19. Mechanisms underlying cerebrovascular effects of cigarette smoking in rats in vivo. Iida M, Iida H, Dohi S, Takenaka M, Fujiwara H. Stroke; 1998 Aug 16; 29(8):1656-65. PubMed ID: 9707209 [Abstract] [Full Text] [Related]
20. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, Varenicline Phase 3 Study Group. JAMA; 2006 Jul 05; 296(1):56-63. PubMed ID: 16820547 [Abstract] [Full Text] [Related] Page: [Next] [New Search]